Docetaxel in Metastatic Urothelial Cancer
Author Information
Author(s): R de Wit, WHJ Kruit, G Stoter, M de Boer, J Kerger, J Verweij
Primary Institution: Rotterdam Cancer Institute and University Hospital
Hypothesis
Is docetaxel an effective treatment for metastatic urothelial cancer in non-chemotherapy-pretreated patients?
Conclusion
Docetaxel is an effective agent in treating metastatic urothelial cell cancer, with a notable response rate.
Supporting Evidence
- Four patients achieved a complete response and five a partial response.
- The overall response rate was 31%.
- The median duration of response was 6 months.
- Toxic effects mainly consisted of neutropenia, which rarely caused complications.
Takeaway
Doctors tested a medicine called docetaxel on patients with a type of cancer that had spread, and it helped some of them get better.
Methodology
Patients with metastatic urothelial cancer received docetaxel 100 mg/m² every 3 weeks, and their responses were evaluated.
Limitations
The study had a small sample size and was limited to non-chemotherapy-pretreated patients.
Participant Demographics
Median age was 61 years, with a range of 45-72 years; 25 men and 5 women participated.
Want to read the original?
Access the complete publication on the publisher's website